News coverage about Heat Biologics (NASDAQ:HTBX) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Heat Biologics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.0063561214859 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Heat Biologics (NASDAQ:HTBX) traded up $0.02 during mid-day trading on Thursday, reaching $0.49. The company had a trading volume of 545,300 shares, compared to its average volume of 609,003. Heat Biologics has a 12 month low of $0.41 and a 12 month high of $3.35.

Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. The company had revenue of $0.47 million for the quarter, compared to analysts’ expectations of $0.50 million. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. analysts predict that Heat Biologics will post -0.38 EPS for the current year.

Separately, Griffin Securities began coverage on Heat Biologics in a research note on Tuesday, September 12th. They issued a “buy” rating and a $2.25 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $2.13.

TRADEMARK VIOLATION NOTICE: “Heat Biologics (HTBX) Earns Daily Media Impact Score of 0.14” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/30/heat-biologics-htbx-earns-daily-media-impact-score-of-0-14.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Insider Buying and Selling by Quarter for Heat Biologics (NASDAQ:HTBX)

Receive News & Stock Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related stocks with our FREE daily email newsletter.